Neumora Therapeutics (NMRA) Competitors $0.81 +0.03 (+3.68%) Closing price 03:14 PM EasternExtended Trading$0.81 +0.00 (+0.25%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. SEPN, SIGA, ORGO, ATYR, KMDA, CGEM, ATAI, MREO, PGEN, and RAPPShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Septerna (SEPN), Siga Technologies (SIGA), Organogenesis (ORGO), aTyr Pharma (ATYR), Kamada (KMDA), Cullinan Therapeutics (CGEM), atai Life Sciences (ATAI), Mereo BioPharma Group (MREO), Precigen (PGEN), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. Its Competitors Septerna Siga Technologies Organogenesis aTyr Pharma Kamada Cullinan Therapeutics atai Life Sciences Mereo BioPharma Group Precigen Rapport Therapeutics Septerna (NASDAQ:SEPN) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk. Do analysts prefer SEPN or NMRA? Septerna presently has a consensus price target of $26.75, indicating a potential upside of 136.73%. Neumora Therapeutics has a consensus price target of $9.29, indicating a potential upside of 1,044.97%. Given Neumora Therapeutics' higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22 Which has better earnings & valuation, SEPN or NMRA? Septerna has higher revenue and earnings than Neumora Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$1.08M466.23-$71.80MN/AN/ANeumora TherapeuticsN/AN/A-$243.79M-$1.61-0.50 Do insiders and institutionals believe in SEPN or NMRA? 47.7% of Neumora Therapeutics shares are held by institutional investors. 4.3% of Septerna shares are held by company insiders. Comparatively, 26.8% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is SEPN or NMRA more profitable? Septerna's return on equity of 0.00% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SepternaN/A N/A N/A Neumora Therapeutics N/A -84.79%-77.57% Does the media favor SEPN or NMRA? In the previous week, Neumora Therapeutics had 1 more articles in the media than Septerna. MarketBeat recorded 3 mentions for Neumora Therapeutics and 2 mentions for Septerna. Neumora Therapeutics' average media sentiment score of 1.02 beat Septerna's score of 0.90 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySepterna beats Neumora Therapeutics on 6 of the 11 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$126.52M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-0.5021.4227.3820.03Price / SalesN/A285.81422.31120.16Price / CashN/A41.9536.6357.47Price / Book0.467.518.085.67Net Income-$243.79M-$55.05M$3.16B$248.47M7 Day Performance1.45%3.16%2.12%2.90%1 Month Performance9.14%5.92%4.43%5.75%1 Year Performance-91.69%5.82%35.62%21.36% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics2.6169 of 5 stars$0.81+3.7%$9.29+1,045.0%-92.0%$126.52MN/A-0.50108News CoveragePositive NewsGap UpSEPNSepterna1.7165 of 5 stars$10.57+0.6%$26.75+153.1%N/A$471.00M$1.08M0.00N/ASIGASiga Technologies1.5901 of 5 stars$6.52+0.9%N/A-14.4%$465.79M$138.72M9.7340ORGOOrganogenesis4.0982 of 5 stars$3.66-0.3%$6.00+63.9%+52.3%$465.55M$458.76M-21.53950ATYRaTyr Pharma2.9858 of 5 stars$5.07+0.8%$20.20+298.4%N/A$451.23M$230K-6.2653High Trading VolumeKMDAKamada4.1674 of 5 stars$7.75+0.5%$14.67+89.2%+54.8%$445.70M$160.95M26.72360Positive NewsCGEMCullinan Therapeutics1.5362 of 5 stars$7.53-3.0%$30.00+298.4%-52.4%$444.35MN/A-2.5930Positive NewsGap UpATAIatai Life Sciences3.1375 of 5 stars$2.19-0.5%$8.67+295.7%+111.5%$438.75M$310K-2.4180News CoverageAnalyst ForecastOptions VolumeMREOMereo BioPharma Group1.9782 of 5 stars$2.71+1.9%$7.60+180.4%-16.8%$430.89M$10M-38.7140PGENPrecigen3.7194 of 5 stars$1.42flat$6.00+322.5%+8.1%$419.16M$3.92M-2.54190News CoverageRAPPRapport Therapeutics1.9466 of 5 stars$11.37-0.5%$32.67+187.3%-52.8%$415.01MN/A-3.30N/ANews CoverageGap Up Related Companies and Tools Related Companies Septerna Competitors Siga Technologies Competitors Organogenesis Competitors aTyr Pharma Competitors Kamada Competitors Cullinan Therapeutics Competitors atai Life Sciences Competitors Mereo BioPharma Group Competitors Precigen Competitors Rapport Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
